By incorporating appropriate drug (s) into lipid (biobased) nanocarriers, one obtains a
combination therapeutic for dementia treatment that targets certain cell-surface scavenger …

Past published studies have already documented that, subsequent to the intravenous
injection of colloidal lipid nanocarriers, apolipoprotein (apo) AI is adsorbed from the blood …

Background: Recent studies show links between metabolic syndrome and Alzheimer's
disease (AD) neuropathology. Understanding the link between vascular-related health …

Abstract Background About 40–50% of patients with amnestic mild cognitive impairment
(MCI) are found to have no significant Alzheimer's pathology based on amyloid PET …

Objectives Alzheimer's disease (AD) is characterised by amyloid-beta accumulation (A), tau
aggregation (T) and neurodegeneration (N). Vascular (V) burden has been found …

Due to the complexity of Alzheimer's disease, multiple cellular types need to be targeted
simultaneously in order for a given therapy to demonstrate any major effectiveness …

Owing to the complexity of neurodegenerative diseases, multiple cellular types need to be
targeted simultaneously in order for a given therapy to demonstrate any major effectiveness …

Amyloid-β (Aβ) and cerebral small vessel disease (CSVD) commonly coexist. They can
occur independently by chance, or may interact with each other. We aimed to determine …

Over the past decades, a frequent co-morbidity of cerebrovascular pathology and
Alzheimer's disease has been observed. Numerous published studies indicate that the …

Background: Subcortical vascular cognitive impairment (sVCI), caused by cerebral small
vessel disease, accounts for the majority of vascular cognitive impairment, and is …